

ExoCoBio receives Japanese patent for alleviating dermatitis with exosome-based medicines

09 May 2022 | News

To prove the technological feasibility of ExoSCRT for the mass-production of the world's best exosomes with high efficacy



ExoCoBio Inc. has received from Japanese Patent Office the patent which claims that stem cell-derived exosome is proved as effective ingredient for alleviating dermatitis.

The patent is the result of the vigorous R&D efforts made to develop therapeutic medicines with higher efficacy and safety than currently known ones in relation to dermatitis with itching and inflammation. South Korea-based startup ExoCoBio found that the technology in the patent would solve the safety problem arising from stem cell or stem cell conditioned media by using ExoSCRT exosomes isolated from adipose stem cell conditioned media and thus prove the effectiveness of exosomes for prevention, improvement, alleviation or treatment of dermatitis.

Furthermore, it is anticipated that the ExoSCRT exosomes will play a scientifically pivotal role as new medicine for dermatitis treatment.

Among therapeutic medicines currently marketed for the dermatitis are steroid, antihistamine, and immunosuppressive cyclosporine A etc. There are, however, growing concerns about serious side effects in relation with the use of them such as atrophoderma, vasodilation, loss of pigment, hypersensitivity after injection, tolerance and neutropenia etc. On the contrary, exosome-based medicines are expected to provide the fundamental treatment for inflammatory skin diseases without any serious side effect.

ExoCoBio expects that the patent will lay a technological foundation for regenerative aesthetics and medicines relating to prevention, alleviation or treatment of dermatitis. Furthermore, ExoCoBio anticipates its business opportunity in Japan for ExoSCRT exosomes based on the patent in the cosmetic and pharmaceutical fields.